Natera, Germany’s Pirche Partner on Testing for Kidney Transplant Risk and Monitoring

The collaboration aims to connect Pirche's TxPredictor risk stratification platform with Natera's Prospera monitoring test.

German bioinformatics company Pirche and Natera will collaborate to integrate pre-transplant immunological risk assessment with post-transplant molecular monitoring in kidney transplant care.

Under the agreement, announced June 19, Pirche will lead customer education efforts around using its TxPredictor platform alongside Natera’s Prospera test, a donor-derived cell-free DNA assay used to detect organ rejection after transplantation.

Financial terms of the collaboration were not disclosed.

“Integrating the predictive power of our TxPredictor platform with Natera’s Prospera test gives transplant teams an unprecedented toolkit to personalize immunosuppression therapies and ultimately protect graft longevity,” Thomas Klein, Pirche founder and CEO, said in a statement.

Berlin-based Pirche’s TxPredictor platform uses proprietary algorithms to analyze histocompatibility and generate immunological risk scores before transplantation. Natera’s Prospera test provides molecular surveillance after transplant by measuring dd-cfDNA levels in a patient’s blood as a marker of organ injury or rejection.